Aethlon Medical, Inc. has announced its financial results for the fiscal fourth quarter ended March 31, 2025. The company reported a net loss attributable to common stockholders of approximately $13.4 million for the period, compared to a net loss of about $12.2 million in the same period the previous year. The comprehensive loss for the quarter was approximately $13.4 million, up from $12.2 million the previous year. Aethlon Medical also reported a decrease in operating expenses for the fiscal year ended March 31, 2025. Operating expenses amounted to approximately $9.3 million, representing a reduction of $3.3 million or approximately 26% compared to $12.6 million for the previous fiscal year. This decline was primarily due to a reduction in payroll and related expenses, professional fees, and general and administrative costs, with payroll expenses alone reduced by about $1.3 million. As of March 31, 2025, Aethlon Medical had a cash balance of approximately $5.5 million. The company has streamlined its operations, reducing operating expenses to focus on its clinical and regulatory goals effectively.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。